Results 151 to 160 of about 36,830 (259)

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. [PDF]

Adv Ther
Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E.   +12 more
europepmc   +1 more source

PDE4 Inhibition in Dermatologic Disease: Impacts Beyond Inflammation

International Journal of Dermatology, EarlyView.
This graphical abstract demonstrates the comprehensive mechanism of PDE4 inhibition in skin physiology. By increasing intracellular cAMP and activating PKA, PDE4 inhibitors exert pleiotropic effects, including immune modulation, pigmentation regulation, barrier enhancement, sensory neuron modulation, and improved wound healing with reduced fibrosis ...
Keana Khodadad, Nicole E. Chin, Raj Chovatiya   +2 more
wiley   +1 more source

Long-Term Survival of Methotrexate as First-Line Therapy in Rheumatoid Arthritis, Psoriatic Arthritis and Undifferentiated Arthritis. [PDF]

J Clin Med
Perrotta FM, Ambrosino P, Lubrano E.
europepmc   +1 more source

Prevalence and Characteristics of North American Indigenous Inflammatory Skin Disease: A Systematic Scoping Review

International Journal of Dermatology, EarlyView.
This scoping review synthesizes evidence on atopic dermatitis (AD), psoriasis, and hidradenitis suppurativa in North American Indigenous peoples across 49 studies and 63 clinical trials. Findings reveal consistently high disease burden in AD, marked underrepresentation in trials and guidelines, and five evidence‐based recommendations to advance ...
Rachel Asiniwasis, Jordanna Roesler, Amira Muftah, Aysha Lukmanji, McKenzie Van Eaton, Kavya Yatham, Erin Watson, Eric McMullen, Gregory Kost, Colton Jensen, Oluwatosin Odeshi, Anna Chacon, Dana Slape, Brittany Waller, Kelsey Hinther, Mamata Pandey, Carolyn Jack, Derek K. Chu   +17 more
wiley   +1 more source

[Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis]. [PDF]

Wien Klin Wochenschr
Lindner B, Ausserwinkler M, Siess C, Ammerer K, Esposito M, Hermann J, Hintenberger R, Komposch M, Lanser L, Lechner-Radner H, Peter C, Rega-Kaun G, Reinhart-Mikocki D, Schedl S, Stögerer-Lanzenberger M, Thiel J, Niessner A.   +16 more
europepmc   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Gender differences in illness acceptance and coping strategies among patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis: a cross-sectional survey study. [PDF]

Rheumatol Int
Lindgren LH, Hammer NM, Flurey CA, Jensen KV, Andersen L, Esbensen BA.   +5 more
europepmc   +1 more source

Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. [PDF]

BMC Musculoskelet Disord, 2020
Friedberger A, Figueiredo C, Grimm A, d'Oliveira I, Bäuerle T, Rech J, Kleyer A, Simon D, Uder M, Schett G, Engelke K.   +10 more
europepmc   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source